Literature DB >> 11530892

Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions.

K L Leenders1, W H Oertel.   

Abstract

Parkinson's disease is one of the most frequent neurodegenerative brain diseases. Its time course is slow and is characterized by progressive loss of dopaminergic and other brainstem neurons resulting in malfunctioning of the cerebral neuronal systems responsible for motor functions. The clinical signs are slowness of movement, muscle rigidity and rest-tremor amongst other features. The cause of the disease is unknown, but recently involvement of genetic factors is being researched. Positron emission tomography (PET) allows in vivo determination of striatal dopaminergic activity. This has increased our insight in the pathophysiology of the disease and permits direct study of disease progression at a biochemical level and equally to monitor whether potential neuroprotective interventions are indeed effective. Thus far no drug has emerged but promising substances are currently being studied.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11530892      PMCID: PMC2565383          DOI: 10.1155/NP.2001.99

Source DB:  PubMed          Journal:  Neural Plast        ISSN: 1687-5443            Impact factor:   3.599


  9 in total

1.  Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease.

Authors:  Domenico Aquino; Valeria Contarino; Alberto Albanese; Ludovico Minati; Laura Farina; Marina Grisoli; Luigi Romita; Antonio Emanuele Elia; Antonio Elia; Maria Grazia Bruzzone; Luisa Chiapparini
Journal:  Neurol Sci       Date:  2013-12-11       Impact factor: 3.307

2.  Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait.

Authors:  J M Hausdorff; J D Schaafsma; Y Balash; A L Bartels; T Gurevich; N Giladi
Journal:  Exp Brain Res       Date:  2003-01-22       Impact factor: 1.972

3.  Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Xiaoming Hu; Dan Zhang; Hao Pang; W Michael Caudle; Yachen Li; Huiming Gao; Yuxin Liu; Li Qian; Belinda Wilson; Donato A Di Monte; Syed F Ali; Jing Zhang; Michelle L Block; Jau-Shyong Hong
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

4.  Alpha-lipoic acid potently inhibits peroxynitrite-mediated DNA strand breakage and hydroxyl radical formation: implications for the neuroprotective effects of alpha-lipoic acid.

Authors:  Zhenquan Jia; Hong Zhu; Michael J Vitto; Bhaba R Misra; Yunbo Li; Hara P Misra
Journal:  Mol Cell Biochem       Date:  2008-12-11       Impact factor: 3.396

5.  Potent upregulation of glutathione and NAD(P)H:quinone oxidoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: protection against neurotoxicant-elicited cytotoxicity.

Authors:  Zhenquan Jia; Seema Hallur; Hong Zhu; Yunbo Li; Hara P Misra
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

6.  The perception of passive motion in Parkinson's disease.

Authors:  Jürgen Konczak; Kimberly Krawczewski; Paul Tuite; Matthias Maschke
Journal:  J Neurol       Date:  2007-04-10       Impact factor: 4.849

7.  Genetics of Parkinson's disease.

Authors:  Thomas Gasser
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

8.  Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration?

Authors:  Xi Gao; Xiaoming Hu; Li Qian; Sufen Yang; Wei Zhang; Dan Zhang; Xuefei Wu; Alison Fraser; Belinda Wilson; Patrick M Flood; Michelle Block; Jau-Shyong Hong
Journal:  Environ Health Perspect       Date:  2008-05       Impact factor: 9.031

Review 9.  New hope for Parkinson's disease treatment: Targeting gut microbiota.

Authors:  Hong-Xia Fan; Shuo Sheng; Feng Zhang
Journal:  CNS Neurosci Ther       Date:  2022-07-13       Impact factor: 7.035

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.